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Abstract
Background
Amniotic fluid is clinically accessible via amniocentesis and its protein composition may cor-
respond to birth timing. Early changes in the amniotic fluid proteome could therefore be
associated with the subsequent development of spontaneous preterm delivery.
Objective
The main objective of this study was to perform unbiased proteomics analysis of the associ-
ation between mid-trimester amniotic fluid proteome and spontaneous preterm delivery and
gestational duration, respectively. A secondary objective was to validate and replicate the
findings by enzyme-linked immunosorbent assay using a second independent cohort.
Methods
Women undergoing a mid-trimester genetic amniocentesis at Sahlgrenska University Hos-
pital/O¨ stra between September 2008 and September 2011 were enrolled in this study,
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designed in three analytical stages; 1) an unbiased proteomic discovery phase using LC-
MS analysis of 22 women with subsequent spontaneous preterm delivery (cases) and 37
women who delivered at term (controls), 2) a validation phase of proteins of interest identi-
fied in stage 1, and 3) a replication phase of the proteins that passed validation using a sec-
ond independent cohort consisting of 20 cases and 40 matched controls.
Results
Nine proteins were nominally significantly associated with both spontaneous preterm deliv-
ery and gestational duration, after adjustment for gestational age at sampling, but none of
the proteins were significant after correction for multiple testing. Several of these proteins
have previously been described as being associated with spontaneous PTD etiology and six
of them were thus validated using enzyme linked immunosorbent assay. Two of the proteins
passed validation; Neutrophil gelatinase-associated lipocalin and plasminogen activator
inhibitor 1, but the results could not be replicated in a second cohort.
Conclusions
Neutrophil gelatinase-associated lipocalin and Plasminogen activator inhibitor 1 are poten-
tial biomarkers of spontaneous preterm delivery and gestational duration but the findings
could not be replicated. The negative findings are supported by the fact that none of the nine
proteins from the exploratory phase were significant after correction for multiple testing.
Introduction
One of the major problems in obstetrics is preterm delivery (PTD, < 37 weeks of gestation),
with a global annual estimated incidence of 15 million and 1 million associated neonatal deaths
[1]. PTD can either be iatrogenic (medically indicated) [2] or spontaneous in origin [3], where
the latter accounts for 75% of all PTD [4]. Multiple distinct pathways and complex biological
events within several compartments (maternal blood, genital tract, placenta, amniotic fluid
and the fetus) contribute to the development of spontaneous PTD [5–9], but these are not yet
fully elucidated.
Mid-trimester amniocentesis is performed for genetic testing and provides a unique win-
dow into the amniotic fluid milieu of women with normal pregnancies and pregnancies des-
tined to deliver preterm. The amniotic fluid surrounds the developing fetus [10] and is in close
proximity to the placenta, which reflects a steadily developing organ with a major impact on
birth timing [11]. Proteomic profiling of the amniotic fluid composition in early gestation may
provide insight into basic biological mechanisms, detect different pathological conditions [12]
and increase our understanding of biological factors that contribute to gestational duration.
Furthermore, it may identify early biomarkers of spontaneous PTD and increase our knowl-
edge about associated pathways [13–16].
Development of a suite of “-omics” platforms, such as genomics, proteomics and metabolo-
mics, have enabled the unbiased discovery of complex networks associated with healthy and
abnormal pregnancies [14, 17]. Proteomics provides a unique opportunity to explore the
whole proteome encoded by the genome [18, 19]. A large number of differences in the proteins
quality, quantity [20], function and structure can be characterized [18, 19], which provides a
more comprehensive picture of biological events [21] during gestation. Proteomics has previ-
ously been used to diagnose intra-amniotic inflammation in women with subsequent
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spontaneous PTD [22–24] as well as in women with symptoms of preterm labor (PTL) and
preterm prelabor rupture of membranes (PPROM) at risk for spontaneous PTD [25]. Further-
more, proteomics has enabled the identification of infectious pathways associated with histo-
logic chorioamnionitis in women with PPROM [26, 27]. However, only a few studies have
analyzed the mid-trimester amniotic fluid proteome in relation to spontaneous PTD in single-
tons [28, 29]. Fotopoulou et al. identified seven clusters on three types of protein chips that
were significantly different between women with a subsequent spontaneous PTD and women
who delivered at term. However, they were unable to identify the individual proteins or pep-
tides of these clusters [28]. In a prior study, our group used a pooled sample strategy in which
C-reactive protein emerged as a significant and interesting candidate, but results in the valida-
tion phase were non-significant [29].
The ability to predict women at increased risk for spontaneous PTD remains poor despite
extensive research efforts [14]. The main objective of this study was to perform unbiased prote-
omics analysis of the mid-trimester amniotic fluid proteome and to investigate its association
with subsequent spontaneous PTD and gestational duration. A secondary aim was to validate
and replicate the findings using a second independent cohort, analyzed by enzyme-linked
immunosorbent assay (ELISA).
Materials and methods
Description of the cohort
A total of 1546 women underwent transabdominal amniocentesis for genetic purposes at 14–19
weeks of gestation at Sahlgrenska University Hospital/O¨stra, Gothenburg, Sweden between Sep-
tember 2008 and September 2011. Clinical indications for amniocentesis were advanced maternal
age, abnormal first-trimester combined screening, family history of chromosomal abnormalities
or genetic diseases, or anxiety about potential chromosomal abnormalities. Women were offered
enrollment if they were� 18 years of age and had a viable singleton pregnancy. Women were
ineligible (n = 425) for the following reasons: i) infection with human immunodeficiency virus,
hepatitis B virus or hepatitis C virus, ii) suspected or confirmed congenital fetal abnormality,
and/or iii) clinical amniocentesis at times prior to study start. Women were excluded from the
study (n = 497) if they, i) declined participation, ii) were unable to understand the written and
oral information in Swedish, iii) had an insufficient amniotic fluid sample, or iv) had an initial
twin gestation with fetal demise of one twin or with vanishing twin.
Medical records were abstracted from all eligible subjects (n = 624) at inclusion and after
delivery to obtain information on subjects’ demographics and maternal health, as well as preg-
nancy, delivery and neonatal outcomes. Women who had a termination of pregnancy (n = 12)
or were lost to follow-up (n = 6) were excluded. Women were also excluded with certain
maternal diseases (e.g. hypo- and hyperthyroidism, diabetes mellitus, preeclampsia, uterine
anomaly, multiple sclerosis, autoimmune system diseases, rheumatism, ulcerative colitis,
hemostatic disorders, syphilis, renal disease, leukemia, severe asthma, hypertension, hereditary
chromosomal defects, vitamin D deficiency and epilepsy), fetal complications (congenital
anomaly and fetal growth restriction), and sampling or analytical deviations (discolored amni-
otic fluid at sampling due to blood contamination) and where sample handling deviated from
the study protocol.
Cohort selection for the exploratory and validation phases
Women were categorized into two groups; women with PTD (n = 38) and women with a term
delivery (n = 568). From the group of women with a PTD, women with iatrogenic PTD
(n = 9), and women who fulfilled the exclusion criteria described above (n = 6) were excluded,
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leaving 23 women with a spontaneous PTD to constitute the case group. To achieve a greater
separation in phenotype between cases and controls and a more homogenous control group,
the group of women with a delivery at term were limited to women delivering between 38+0
and 41+6 gestational weeks (n = 524). A random selection of 120 controls was then performed
and exclusion criteria applied; from this group, every third subject was selected to constitute
the final control group. During the proteomic analytical stage, one case of spontaneous PTD
and 3 controls had to be excluded due to a broken injection needle in the HPLC system and
other technical difficulties with sample processing, leaving 22 cases and 37 controls in the final
study cohort that would be used for the exploratory and validation phases (Fig 1).
Cohort selection for the replication phase
For the replication phase, a second independent cohort of amniotic fluid samples was used
from women undergoing genetic amniocentesis at 14–19 weeks gestation at Sahlgrenska
Fig 1. Selection and application of inclusion and exclusion criteria to subjects in the cohort. This flowchart illustrates the selection and application of inclusion and
exclusion criteria to subjects of the cohort.
https://doi.org/10.1371/journal.pone.0232553.g001
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University Hospital/O¨stra, Gothenburg, Sweden between September 2008 and July 2017. This
cohort included 24 women with spontaneous PTD; 23 women who were identified in the sec-
ond cohort and the single spontaneous PTD case from the exploratory phase cohort that was
not analyzed by proteomics, due to technical difficulties with sample processing. Eligibility and
exclusion criteria as described above were applied and four cases of spontaneous PTD were
excluded, leaving 20 cases of spontaneous PTD in the final case group of the replication phase.
Cases were matched to healthy controls in a 1:2 ratio using the following criteria; a) maternal
age at sampling (± 2 years), b) parity (primiparous/multiparous), c) gestational age at sampling
(± 3 days), and d) whether the pregnancy was conceived using in vitro fertilization (IVF; yes/
no), choosing the preceding and subsequent control based on date of sampling. Matching was
successful except for three cases where gestational age at sampling had to be extended by one to
two days for the matched controls. There was no overlap in regards to the study cohorts.
Sample collection
Ultrasound-guided transabdominal amniocentesis was performed on all participants and an
additional three milliliters (mL) of amniotic fluid was collected for the purposes of this study.
The amniotic fluid was immediately stored at 4–8˚C until processing. Samples were then cen-
trifuged for 20 minutes at 12,000 g at 4˚C to remove cells and debris. Pellets and supernatants
were frozen at -80˚C awaiting analysis.
Ethics statement
The study was approved by the Central Ethics Review Board at the University of Gothenburg,
Sweden (Dnr O¨ 639–03, T 318–08, T 694–11). Written informed consent was obtained from
all women who met inclusion criteria and agreed to participate.
Amniotic fluid assessment
Fig 2 outlines the study design beginning with proteomics analyses (stage 1, exploratory
phase), followed by ELISA validation (stage 2, validation phase) and then determining whether
the proteins successfully validated were differentially expressed in a second, independent
cohort (stage 3, replication phase).
Stage 1: Exploratory phase—proteomic analysis. In brief, individual samples were
immunodepleted and digested with trypsin and lys C. Individual amniotic fluid samples were
tagged and multiplexed using iTRAQ reagents, which are amine-specific and can label four
biological samples to enable simultaneous identification and quantitation within pooled multi-
plexed samples. The digested and tagged peptide samples were subjected to high pH fraction-
ation and each fraction was analyzed using reverse phase high performance liquid
chromatography (LC)-mass spectrometry (MS) hyphenated to MS (S1 File and S1 Fig).
Each sample was supplemented with protease inhibitors (Complete Mini, EDTA-free Pro-
tease Inhibitor Cocktail; Roche Diagnostics, Basel, Switzerland) and filtered using centrifugal
filterswith 0.22 μm PVDF membrane (Merck Millipore, Bedford, USA) to remove potential
particulate matter. Total protein concentration was determined using the BCA Protein Assay
Kit (Sigma Aldrich, USA). An equal amount of protein was taken from each sample for immu-
nodepletion of 14 abundant plasma proteins using 4.6 × 100 mm column Multiple Affinity
Removal System (MARS) Hu-14 (Agilent, Palo Alto, USA) according to the manufacturer’s
instructions. Samples were supplemented with 0.1% Rapigest (Waters Milford, USA), buffered
with triethylammonium bicarbonate, pH 8,5 (Sigma Aldrich, St. Louis, USA), reduced by 5
mM tris-(2-carboxyethyl)phosphine (Sigma Aldrich, St. Louis, USA) and the thiol groups were
blocked with S-methyl methanethiosulfonate (Sigma Aldrich, St. Louis, USA). Protein samples
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were digested with LysC (Promega, Madison, USA) for 4 hours at 37˚C. Subsequently, trypsin
(Promega, Madison, USA) was added and proteins were digested overnight.
An iTRAQ 4-plex kit (AB Sciex, Foster City, USA) was used to prepare 20 multiplexed sam-
ples. Each multiplex contained a global internal standard, pool of all samples, at the 114
iTRAQ channel and three individual amniotic fluid samples at iTRAQ channels 115, 116 and
117. The high pH fractionation of multiplexed samples was performed on an UltiMate3000
HPLC analytical system (Thermo Scientific, Bremen, Germany). Peptides were injected in
mobile phase A (2% ACN, 20 mM ammonium formate) on a 2.1 × 100 mm column Xterra MS
Fig 2. Schematic overview of the three analytical stages. Samples were initially analyzed in the exploratory phase by
proteomics. Significant proteins were validated by ELISA using the same cohort of samples. Successfully validated
proteins alterations were subjected for replication using a second independent cohort.
https://doi.org/10.1371/journal.pone.0232553.g002
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C18, 3.5 μm (Waters, Milford, USA) and separated at 0.3 mL/min using a 40-min gradient from
3 to 50% mobile phase B (80% ACN, 20 mM ammonium formate) into 32 subfractions collected
between 6–30 minutes. The subfractions were pooled into 8 fractions and analyzed using an Ulti-
Mate 3000 RSLCnano system connected to a Q-Exactive Plus mass spectrometer (Thermo Scien-
tific, Bremen, Germany). Peptides were loaded in 2% ACN, 0.1% TFA onto a PepMap100
ViperTrap 3 μm (Thermo Scientific, Bremen, Germany) pre-column and eluted on a 0.075 × 500
mm analytical column Acclaim Pep Map RSLC C18, 2 um (Thermo Scientific, Bremen, Ger-
many) using a gradient formed by mobile phase A (2% ACN, 0.1% FA) and mobile phase B (80%
ACN, 0.1% FA). Gradient run from 6 to 44% of mobile phase B in 60 minutes at the flow rate of
200 nl/min. The MS analysis was performed in the information dependent acquisition mode
using the ten most intensive precursors for fragmentation (MS2). All samples were analyzed in
technical triplicates. Peptide identification and quantitation were conducted in the Max Quant
software version 1.5.2.8 using the reverse decoy mode and integrated false discovery rate analysis.
The data was searched against the UniProtKB/Swiss-Prot database (human, canonical included,
download September 3, 2015). Intensities of iTRAQ reporter ions were corrected using isotope
factors supplied with the iTRAQ kit. The sample ratio to global internal standard was calculated
from all reporter ion intensities. Proteins identified by the reverse database and potential contam-
inants were further filtered in order to obtain the final dataset.
Stages 2 and 3: The validation and replication phases. ELISA kits were chosen with a
working range to include the most likely concentration ranges in amniotic fluid for each pro-
tein. Second, ELISA kits were tested to determine if matrix interference might occur from
another protein present in amniotic fluid that could confound results interpretation. In three
cases (insulin-like growth factor-binding protein 5 (IGFBP-5), insulin-like growth factor-bind-
ing protein 7 (IGFBP-7) and semaphorin-3B (SEMA A (V))), either linear dilution and/or
spike-and-recovery approaches yielded non-linear results, indicating that there was specific
interference by a factor present within the amniotic fluid samples (Human IGFBP-5,
(KA1727) Novus Biologicals, Littleton, CO, USA; Human IGFBP-7 (NBP2-62762) Novus Bio-
logicals Littleton, CO, USA; Human SEMA3B/SemA (EKH4388) Nordic Biosite, Ta¨by, Swe-
den). Therefore, efforts were concentrated on validating candidate proteins where it could be
confirmed that the commercially available ELISA kits yielded quantitative and replicable
results: extracellular superoxide dismutase [Cu-Zn] (EC-SOD), lipocalin-15 (LCN15), microfi-
bril-associated glycoprotein 4 (MFAP4), neutrophil gelatinase-associated lipocalin (NGAL),
plasminogen activator inhibitor 1 (PAI-1) and urotensin-2 (U-II), with the proteins short pro-
tein/gene name within parenthesis (S1 Table).
Amniotic fluid samples were analyzed in duplicate within 24 hours of thawing. Analyses
were performed according to the manufacturer’s instructions and laboratory personnel were
blinded to case-control status and other clinical data. Amniotic fluid dilutions used and the
working range of each kit (S2 Table) were as follows: EC-SOD (dilution 1:50; standard curve
range 0.625–40 ng/mL), LCN15 (dilution 1:10; standard curve range 18.75–1200 pg/mL),
MFAP4 (dilution 1:10; standard curve range 0.313–20 ng/mL), NGAL (dilution 1:200; stan-
dard curve range 0.003–0.040 ng/mL), PAI-1 (dilution 1:10; standard curve range 0.31–20 ng/
mL) and U-II (dilution 1:20; standard curve range 15.6–1000 pg/mL). Samples found to be
above or below the detection limit were re-analyzed in a higher or lower sample dilution. Can-
didate proteins alterations that were successfully validated, were subjected to replication.
Statistical analyses
Subject characteristics were compared using Mann Whitney U test, Chi-Square and Fisher’s
exact test. Pearson correlation was used to analyze the correlation between log transformed
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protein concentration or intensity ratio and gestational age at sampling and gestational dura-
tion, respectively, for both cohorts. Student’s t-test or analysis of covariance (ANCOVA) were
used to compare means of log transformed protein concentrations between cases and controls
in the cohort used for the exploratory and validation phases. A linear mixed model was used in
the second cohort of matched data for the replication phase. The significance level was set to
p<0.05 using a two-sided alternative hypothesis. All statistical analyses were performed in
SPSS 25.0 for Windows (SPSS Inc, USA) and R version 3.3.1. The data was graphically dis-
played using the Software Perseus version 1.5.1.6.
Results
Stage 1: The exploratory phase
Maternal and neonatal characteristics of the cohort used in the exploratory and validation
phases (stages 1 and 2) are presented in Table 1. Women delivering preterm were significantly
older than the women delivering at term, but otherwise there were no significant differences
between the groups for parity, use of in vitro fertilization (IVF), body mass index (BMI), smok-
ing, rate of previous PTD, gestational age at sampling, mode of delivery, neonatal sex or Apgar
score.
A total of 43,854 MS/MS spectra were identified with an average number of 3,185 proteins
per multiplex after filtering for reverse and contaminant proteins. Next, selection criteria were
applied to identify the most likely protein candidates in mid-trimester amniotic fluid that may
be correlated with spontaneous PTD or gestational duration. The final data set after filtering
consisted of 1,111 quantified proteins with at least 2 valid values out of 3 and CV< 20% in at
least 75% in both groups. After filtering, 8% of the data were missing and were imputed before
normalization using the mean of data in replicates (if present) or with median of the total data
Table 1. Maternal and neonatal characteristics of the cohort.
Variable Spontaneous preterm delivery (n = 22) Term delivery (n = 37) p
Gestational duration (weeks+days) 35+5 (33+5–36+5) 40+1 (39+2–41+1)
Birth weight (grams) 2575 (2358–2870) 3540 (3260–3778)
Maternal age at sampling (years) 38 (36–41) 36 (35–38) 0.029
Nulliparous 14 (63.6%) 27 (73.0%) 0.451
IVF 4 (18.2%) 1 (2.7%) 0.059
Maternal BMI at first prenatal visit 24.6 (23.6–26.9) 23.6 (20.9–26.6) 0.215
Smoking at first prenatal visit 2 (9.1%) 1 (2.7%) 0.549
Previous preterm delivery 3 (13.6%) 1 (2.7%) 0.141
Gestational age at sampling (weeks+days) 15+4 (15+0–16+2) 15+5 (15+2–16+2) 0.460
Mode of delivery
Vaginal delivery 19 (86.4%) 28 (75.7%) 0.506
Vacuum extraction 0 (0.0%) 3 (8.1%) 0.286
Cesarean section 3 (13.6%) 6 (16.2%) 1.000
Neonatal sex 0.564
Male 9 (40.9%) 18 (48.6%)
Female 13 (59.1%) 19 (51.4%)
Apgar score < 7 at 5 min 0 (0.0%) 2 (5.4%) 0.524
Continuous variables were analyzed using a Mann-Whitney U Test and are presented as the median (interquartile range; IQR). Categorical variables were analyzed
using Pearson Chi-Square or Fisher’s Exact Test (when�5 individuals) and are shown as N (%).Bold text indicate statistical significance at p<0.05 using a two-sided
alternative hypothesis.
https://doi.org/10.1371/journal.pone.0232553.t001
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set. After imputation, data were subjected to LOESS normalization in R. In order to maximize
the chances of identifying proteins correlated to spontaneous PTD, data was filtered to require
a difference of intensity ratio between cases and controls of |Δ|�0.2. A total of 33 proteins met
these filtering criteria (S3 Table).
Analysis of crude data, adjusting for gestational age at sampling, revealed significantly
higher concentrations of LCN15 (Δ = 0.41, p = 0.039) and MFAP4 (Δ = 0.23, p = 0.040) and
significantly lower concentrations of EC-SOD (Δ = -0.26, p = 0.004), IGFBP-5 (Δ = -0.22,
p = 0.046), IGFBP-7 (Δ = -0.32, p = 0.043), NGAL (Δ = -0.28, p = 0.044), PAI-1 (Δ = -0.29,
p = 0.001), SEMA A (V) (Δ = -0.23, p = 0.001) and U-II (Δ = -0.22, p = 0.009) in women with
spontaneous PTD compared to women who delivered at term. Furthermore, a significant neg-
ative correlation was observed between LCN15 (r = -0.345, p = 0.009) and MFAP4 (r = -0.334,
p = 0.011) concentrations and gestational duration, while a significant positive correlation was
seen for EC-SOD (r = 0.385, p = 0.003), IGFBP-5 (r = 0.291, p = 0.029), IGFBP-7 (r = 0.317,
p = 0.017), NGAL (r = 0.289, p = 0.030), PAI-1 (r = 0.426, p = 0.001), SEMA A (V) (r = 0.375,
p = 0.011), and U-II (r = 0.312, p = 0.019) concentrations, respectively (Table 2). Notably,
maternal age was not significantly associated with any of the final protein concentrations.
None of the proteins were significant after correction for multiple testing.
Stage 2: The validation phase
Next, ELISA was used to validate the findings from the proteomics analysis. Significantly
decreased concentrations of MFAP4 (spontaneous PTD: median 6.9 ng/mL (IQR 4.2–8.1) vs
term: median 8.5 ng/mL (IQR 5.6–19.2); p = 0.005), NGAL (spontaneous PTD: median 224.0
ng/mL (IQR 129.3–360.0) vs term: median 372.0 ng/mL (IQR (212.1–527.5); p = 0.011) and
PAI-1 (spontaneous PTD: median 26.8 ng/mL (IQR (20.6–39.5) vs term: median 38.2 ng/mL
(IQR 26.5–80.0); p = 0.010) in women with a spontaneous PTD were observed in the validation
phase. NGAL concentrations were also associated with gestational age at sampling (p = 0.038)
and adjusted accordingly (S4 Table). Validation of MFAP4 showed an opposite effect com-
pared to the exploratory phase with significantly lower concentrations in women with sponta-
neous PTD compared to women with a term delivery during validation. No differences were
Table 2. The final proteins from the proteomic analysis.
Protein Short protein/gene name Primary accession number Δ pΔ r pr
Increased Protein Expression
Lipocalin-15 LCN15 Q6UWW0 0.41 0.039 -0.345 0.009
Microfibril-associated glycoprotein 4 MFAP4 P55083 0.23 0.040 -0.334 0.011
Decreased Protein Expression
Extracellular superoxide dismutase [Cu-Zn] EC-SOD P08294 -0.26 0.004 0.385 0.003
Insulin-like growth factor-binding protein 5 IGFBP-5 P24593 -0.22 0.046 0.291 0.029
Insulin-like growth factor-binding protein 7 IGFBP-7 Q16270 -0.32 0.043 0.317 0.017
Neutrophil gelatinase-associated lipocalin NGAL P80188 -0.28 0.044 0.289 0.030
Plasminogen activator inhibitor 1 PAI-1 P05121 -0.29 0.001 0.426 0.001
Semaphorin-3B SEMA A (V) Q13214 -0.23 0.001 0.375 0.011
Urotensin-2 U-II O95399 -0.22 0.009 0.312 0.019
The table presents the nine differentially expressed proteins by proteomics analysis that were nominally significantly correlated with both spontaneous PTD and
gestational duration, adjusted for gestational age at sampling.
Δ reflects the difference of intensity ratio between cases and controls and pΔ is the corresponding p value. r is the correlation between intensity ratio and gestational
duration adjusted for gestational age at sampling and pr is the corresponding p value.
https://doi.org/10.1371/journal.pone.0232553.t002
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observed between cases and controls in the validation phase for levels of EC-SOD (spontane-
ous PTD: median 51.5 ng/mL (IQR 41.3–60.0) vs term: median 50.5 ng/mL (IQR 38.8–61.3);
p = 0.367), LCN15 concentrations (spontaneous PTD: median 347.5 pg/mL (IQR 283.1–419.0)
vs term: median 318.8 pg/mL (IQR 262.6–377.5); p = 0.259), or U-II (spontaneous PTD:
median 40.5 pg/mL (IQR 28.0–66.4) vs term: median 39.3 pg/mL (IQR 25.8–90.6); p = 0.317)
(Table 3).
In the exploratory phase, a positive correlation was observed between EC-SOD, NGAL,
PAI-1 and U-II concentrations and gestational duration. This correlation was confirmed in
the validation phase for NGAL (r = 0.28, p = 0.033) and PAI-1 (r = 0.28, p = 0.031), but not for
EC-SOD (r = -0.11, p = 0.390) and U-II (r = 0.18, p = 0.172) (Table 4). Finally, the negative cor-
relation of LCN15 and MFAP4 concentrations and gestational duration observed in the
exploratory phase was not verified in the validation phase; LCN15 (r = -0.12, p = 0.364) and
MFAP4 (r = 0.33, p = 0.011), where MFAP4 again showed an opposite effect compared to the
exploratory phase.
Stage 3: The replication phase
Maternal and neonatal characteristics of the second independent cohort used for the replica-
tion phase (Stage 3) are presented in Table 5. In this second cohort, there were no significant
differences between women with a spontaneous PTD and their matched controls delivering at
term, except the expected difference in gestational duration and birth weight. There were also
no significant differences in characteristics between the cohort used in the exploratory and
Table 3. Distribution of protein concentrations among cases and controls in the validation phase.
Short protein/ gene name Spontaneous preterm delivery (n = 22) Term delivery (n = 37) p
EC-SOD (ng/mL) 51.5 (41.3–60.0) 50.5 (38.8–61.3) 0.367
LCN15 (pg/mL) 347.5 (283.1–419.0) 318.8 (262.6–377.5) 0.259
MFAP4 (ng/mL) 6.9 (4.2–8.1) 8.5 (5.6–19.2) 0.005
NGAL (ng/mL) 224.0 (129.3–360.0) 372.0 (212.1–527.5) 0.011
PAI-1 (ng/mL) 26.8 (20.6–39.5) 38.2 (26.5–80.0) 0.010
U-II (pg/mL) 40.5 (28.0–66.4) 39.3 (25.8–90.6) 0.317
Protein concentrations are shown as median (interquartile range; IQR). p values are obtained with Student’s t-test (or
for NGAL with ANCOVA adjusting for gestational age at sampling) on log transformed values. Bold text indicates
statistical significance at p<0.05 using a two-sided alternative hypothesis and only the significantly altered proteins
have been replicated.
https://doi.org/10.1371/journal.pone.0232553.t003
Table 4. Correlation between protein concentrations and gestational duration in the validation phase.
Short protein/ gene name r p
EC-SOD -0.11 0.390
LCN15 -0.12 0.364
MFAP4 0.33 0.011
NGAL 0.28 0.033
PAI-1 0.28 0.031
U-II 0.18 0.172
Pearson correlation (r) between gestational duration and log transformed protein concentrations controlling for
gestational age at sampling for NGAL. Bold text indicates statistical significance at p<0.05 using a two-sided
alternative hypothesis.
https://doi.org/10.1371/journal.pone.0232553.t004
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validation phases (Stages 1 and 2) and the second cohort used in the replication phase (Stage
3) (S5 Table).
NGAL concentrations (spontaneous PTD: median 398.0 ng/mL (IQR 165.7–502.0) vs term:
median 325.5 ng/mL (IQR 228.3–499.8); p = 0.448) and PAI-1 concentrations (spontaneous
PTD: median 41.4 ng/mL (IQR 26.4–54.8) vs term: median 40.1 pg/mL (IQR 22.4–59.4);
p = 0.718) were not significantly associated with spontaneous PTD in the replication phase
(Table 6). Neither were there any associations between the mid-trimester amniotic fluid con-
centrations of NGAL (r = 0.05; p = 0.722) and PAI-1 (r = -0.10; p = 0.443) and gestational
duration.
Discussion
Studies of amniotic fluid have the potential to provide insights into basic biological mecha-
nisms [12] of a wide range of pregnancy complications [12, 30] and to increase our under-
standing of key biological processes within the amniotic cavity. In a well-controlled study of
mid-trimester amniotic fluid samples, we found a significant association between a lower
Table 5. Maternal and neonatal characteristics of the second cohort.
Variable Spontaneous preterm delivery (n = 20) Term delivery (n = 40) p
Gestational duration (weeks+days) 36+2 (33+1–36+4) 39+6 (39+1–40+2)
Birth weight (grams) 2789 (2120–3229) 3500 (3255–3891)
Matching variables
Maternal age at sampling (years) 36 (33–39) 36 (33–40) 0.863
Nulliparous 12 (60.0%) 24 (60.0%) 1.000
IVF 1 (5.0%) 2 (5.0%) 1.000
Gestational age at sampling (weeks+days) 15+5 (15+0–16+1) 15+5 (15+2–16+0) 0.735
Other variables
Maternal BMI at first prenatal visit 25.9 (21.3–28.1) 23.2 (21.8–26.7) 0.327
Smoking at first prenatal visit 2 (10.0%) 5 (12.5%) 1.000
Previous preterm delivery 3 (15.0%) 4 (10.0%) 0.676
Mode of delivery
Vaginal delivery 12 (60.0%) 27 (67.5%) 0.566
Vacuum extraction 1 (5.0%) 4 (10.0%) 0.656
Cesarean section 7 (35.0%) 9 (22.5%) 0.302
Neonatal sex 1.000
Male 10 (50.0%) 20 (50.0%)
Female 10 (50.0%) 20 (50.0%)
Apgar score < 7 at 5 min 0 (0.0%) 1 (2.5%) 1.000
Continuous variables were analyzed using a Mann-Whitney U Test and are presented as the median (interquartile range; IQR). Categorical variables were analyzed
using Pearson Chi-Square or Fisher’s Exact Test (when�5 individuals) and are shown as N (%).
https://doi.org/10.1371/journal.pone.0232553.t005
Table 6. Distribution of protein concentrations among cases and controls in the replication phase.
Short protein/ gene name Spontaneous preterm delivery (n = 20) Term delivery (n = 40) p
NGAL (ng/mL) 398.0 (165.7–502.0) 325.5 (228.3–499.8) 0.448
PAI-1 (ng/mL) 41.4 (26.4–54.8) 40.1 (22.4–59.4) 0.718
Protein concentrations are shown as median (interquartile range; IQR). p values are obtained with a linear mixed
model on log transformed values and with matched set as random factor.
https://doi.org/10.1371/journal.pone.0232553.t006
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quantity of NGAL and PAI-1 with spontaneous PTD and a shorter gestational duration in the
first cohort, but not in the second, independent cohort. In the exploratory phase, 33 proteins
met the final filtering criteria of which nine proteins (EC-SOD, IGFBP-5, IGFBP-7, LCN15,
MFAP4, NGAL, PAI-1, SEMA A (V) and U-II) were associated with spontaneous PTD and
gestational duration adjusting for gestational age at sampling. However, none of the proteins
from the exploratory phase were significant after correction for multiple testing.
The onset of labor, both at term and at preterm, is initiated by inflammatory processes [31,
32] by a common pathway involving uterine contractility, cervical ripening, decidual and fetal
membrane activation leading to rupture of the chorioamniotic membranes [33]. One funda-
mental difference is though that term labor results from a physiological activation of the com-
ponents of the common pathway, while preterm labor arises from pathologic processes or
stimulus that activate one or more of the components of the common pathway of parturition,
causing an abnormal or disturbed regulation of the maternal inflammatory response. This
may lead to an overproduction of cytokines, chemokines, prostaglandins and proteases [6] but
could similarly cause a dysregulation with pre-term labor as the resultant pathophysiology.
NGAL, also known as Lipocalin 2 [34], is expressed by neutrophils and has the ability to
bind to small extracellular molecules and substances (e.g. lipophilic molecules [35], retinol,
prostaglandins, fatty acids, steroids, iron, and matrix metalloproteinases (MMPs)). Notably,
NGAL expression is higher in the amniotic fluid and trophoblast cells in the late second and
third trimester of women with PTL [27, 36, 37]. In our study, we analyzed samples in the early
second trimester that predated the diagnosis of PTL by weeks to months. An association
between lower levels of NGAL and spontaneous PTD in the mid-trimester is interesting,
because sequestration of iron is a key function important in limiting bacterial growth [38, 39].
An impairment in NGAL might increase the bioavailability of iron in the lower genital tract
and predispose to an ascending infection and spontaneous PTD.
A few of the other candidate proteins associated with spontaneous PTD and gestational
duration in the exploratory phase have also been described in studies of spontaneous PTD or
inflammation. After delivery, a higher concentration of both PAI-1 and LCN-15 has been
found in preterm infants, PAI-1 has also been observed in higher levels in the lungs of preterm
newborns with respiratory distress syndrome [40]. PAI-1 is a serpine protease inhibitor
involved in the cascade that leads to MMP degradation; preventing excessive MMP degrada-
tion is important for limiting tissue injury during infections [41]. Although higher levels of
PAI-1 are detected in preterm infants after birth, a lower level of PAI-I in the mid-trimester
may predispose to spontaneous PTD by allowing excessive MMP-associated tissue injury of
the chorioamniotic membranes and facilitate microbial invasion of the amniotic fluid. In addi-
tion, IGFBP-5 seems to play a key role in controlling cell senescence and cell inflammation
[42] and an increased activity of IGFBP-7 has been associated with cellular senescence and tis-
sue aging [43]. Tissue aging is caused by yet uncharacterized biomolecular pathways of oxida-
tive damage in the placental and fetal membranes and is related to spontaneous PTD and
PPROM [44]. Overall, there is biological rationale for some of these candidate proteins to be
linked to spontaneous PTD or inflammation, but their roles in mid-trimester amniotic fluid
need further investigation.
Mathematical and statistical criteria used to filter and select the potential candidates were
designed to maximize the chances to identify proteins with the greatest separation between
women destined to have a spontaneous PTD and women who delivered at term, but whether
this gestational time frame is the optimal timing for detection of early inflammatory processes
that leads to the subsequent development of spontaneous PTD remains unknown.
The major strength of this study is the strong methodology, including the thorough selec-
tion criteria for cases and controls, the standardized protocols for sample processing and the
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three stages experiment with an exploratory phase followed by a validation phase and a replica-
tion phase using a second cohort. The cohorts used in this study are unique due to their rela-
tively large number of healthy, asymptomatic women with subsequent spontaneous PTD,
large cohorts of healthy women with a delivery at term, and a very low lost to follow-up rate.
The structured and rigorous process of validating the kits for the use of amniotic fluid and
carefully select the ones with the most potential should also be considered as strength.
Limitations of this study are that the enrolled women may not reflect the general population
as they are of a more advanced maternal age and have a higher risk of fetal chromosomal
abnormalities than the overall population. Mid-trimester amniotic fluid samples can however
only be collected in line with clear clinical indications, such as genetic testing, leaving few
other opportunities to collect such samples. By excluding women with known or suspected
fetal abnormalities from the study and women with confirmed anomalies from analysis, the
bias that this introduce has partly been handled. Further, only women who understood Swed-
ish were enrolled. The rate of spontaneous PTD rate differs between ethnicities, which can
affect the generalization. The limitation of the control group to delivery between 38+0 and 41
+6 gestational weeks was based on a case control design but is not optimal from the continu-
ous perspective where gestational duration is studied. Finally, ELISA kits were considered
unsuitable for the use of amniotic fluid for three potentially interesting candidates (SEMA A
(V), IGFBP-5 and IGFBP-7) from the proteomics exploratory phase.
Detection of mid-trimester amniotic fluid proteins associated with birth timing would
open up new possibilities for diagnostic assay development, which would mark a significant
advance in obstetrics. Several of the nine proteins from the exploratory phase have previously
been described as being associated with spontaneous PTD etiology, but, to our knowledge,
none of these proteins have previously been evaluated in mid-trimester amniotic fluid. This
strengthened our decision to validate and replicate the findings even though they were not sig-
nificant after correction for multiple testing. The novel findings of NGAL and PAI-1 as poten-
tial biomarkers for the subsequent development of spontaneous PTD and determination of
gestational duration in the validation phase could not be replicated. It is therefore important
to continue studies of asymptomatic women for the early identification of mid-trimester amni-
otic fluid proteomic markers of spontaneous PTD and gestational duration.
Conclusions
Decreased concentrations of NGAL and PAI-1 were significantly associated with both subse-
quent spontaneous PTD and gestational duration but the findings could not be replicated in a
second independent cohort. Further research is needed to determine the value of mid-trimes-
ter amniotic fluid proteins as potential predictive biomarkers of spontaneous PTD and gesta-
tional duration.
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